Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Boserolimab with or without pembrolizumab in advanced solid tumors
NCT03396445Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2018
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 1, open-label trial of boserolimab in solid tumor, endometrial cancer (EC), Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) and 1 more (17 arms), sponsored by Merck & Co. Primary endpoints: Dose-Limiting Toxicity at 21 days, Adverse Events at 78 months and 1 more. Started Feb 2018; status: completed.
02
Drugs
boserolimab
03
Conditions
solid tumorendometrial cancer (EC)Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03396445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03396445.